Characteristics and outcomes in atorvastatin therapy for chronic subdural hematoma: a national, observational real-world study in China, 2019-2024.

ABSTRACT:

Background

The incidence of chronic subdural hematoma (cSDH) is increasing in the aging population worldwide, where the success of conventional surgical decompression is complicated by high rates of complications and recurrence. The anti-inflammatory properties of atorvastatin make it an attractive, low-cost, and safe medical approach, but limited evidence exists regarding its clinical benefit in cSDH. We aim to evaluate temporal trends, disease characteristics, and clinical outcomes associated with atorvastatin treatment for cSDH in real-world settings in China.

Methods

This was a multicenter registry study of the Chronic Subdural Hematoma (MR-CSDH) in China. Adults received either 20 mg of atorvastatin or not daily for 8 weeks and were followed up for an additional 6 month

SUBMITTER: Liu T 

PROVIDER: S-EPMC12481968 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature